From Wikipedia, the free encyclopedia
Cancer vaccine
ALVAC-CEA vaccine is a
cancer vaccine containing a
canary pox virus (ALVAC) combined with the
carcinoembryonic antigen (CEA)
human gene.[
citation needed]
A phase I trial in 118 patients showed safety in humans.
[1]
References
-
^ Kaufman, Howard L.; Lenz, Heinz-Josef; Marshall, John; Singh, Deepti; Garett, Chris; Cripps, Christine; Moore, Malcolm; von Mehren, Margaret; Dalfen, Richard; Heim, William J.; Conry, Robert M.; Urba, Walter J.; Benson, Al B.; Yu, Maria; Caterini, Judy; Kim-Schulze, Seunghee; Debenedette, Mark; Salha, Danielle; Vogel, Thorsten; Elias, Ileana; Berinstein, Neil L. (2008).
"Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer". Clinical Cancer Research. 14 (15): 4843–4849.
doi:
10.1158/1078-0432.CCR-08-0276.
PMID
18676757.
S2CID
18152383.
External links
This article incorporates
public domain material from
Dictionary of Cancer Terms.
U.S. National Cancer Institute.
|
---|
Development | |
---|
Classes | |
---|
Administration | |
---|
Vaccines | |
---|
Inventors/ researchers | |
---|
Controversy | |
---|
Related | |
---|
|